BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31720935)

  • 1. KRAS Mutation Predicted More Mirometastases and Closer Resection Margins in Patients with Colorectal Cancer Liver Metastases.
    Zhang Q; Peng J; Ye M; Weng W; Tan C; Ni S; Huang D; Sheng W; Wang L
    Ann Surg Oncol; 2020 Apr; 27(4):1164-1173. PubMed ID: 31720935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status.
    Tsilimigras DI; Hyer JM; Bagante F; Guglielmi A; Ruzzenente A; Alexandrescu S; Poultsides G; Sasaki K; Aucejo F; Pawlik TM
    J Am Coll Surg; 2021 Apr; 232(4):590-598. PubMed ID: 33383214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS Mutation Status Dictates Optimal Surgical Margin Width in Patients Undergoing Resection of Colorectal Liver Metastases.
    Margonis GA; Sasaki K; Andreatos N; Kim Y; Merath K; Wagner D; Wilson A; Buettner S; Amini N; Antoniou E; Pawlik TM
    Ann Surg Oncol; 2017 Jan; 24(1):264-271. PubMed ID: 27696170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Biology Rather Than Surgical Technique Dictates Prognosis in Colorectal Cancer Liver Metastases.
    Margonis GA; Sasaki K; Kim Y; Samaha M; Buettner S; Amini N; Antoniou E; Pawlik TM
    J Gastrointest Surg; 2016 Nov; 20(11):1821-1829. PubMed ID: 27384430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
    Margonis GA; Spolverato G; Kim Y; Karagkounis G; Choti MA; Pawlik TM
    Ann Surg Oncol; 2015 Dec; 22(13):4158-65. PubMed ID: 26077912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does KRAS mutation status impact the risk of local recurrence after R1 vascular resection for colorectal liver metastasis? An observational cohort study.
    Procopio F; Viganò L; Cimino M; Donadon M; Del Fabbro D; Torzilli G
    Eur J Surg Oncol; 2020 May; 46(5):818-824. PubMed ID: 31839435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical appraisal of surgical margins according to KRAS status in liver resection for colorectal liver metastases: Should surgical strategy be influenced by tumor biology?
    Rhaiem R; Duramé A; Primavesi F; Dorcaratto D; Syn N; Rodríguez ÁH; Dupré A; Piardi T; Fernández GB; Villaverde AP; Rodríguez Sanjuán JC; Santiago RF; Fernández-Moreno MC; Ferret G; Ben SL; Suárez Muñoz MÁ; Perez-Alonso AJ; Koh YX; Jones R; Martín-Pérez E; Kianmanesh R; Di Martino M
    Surgery; 2024 Jul; 176(1):124-133. PubMed ID: 38519408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
    JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS mutational status impacts pathologic response to pre-hepatectomy chemotherapy: a study from the International Genetic Consortium for Liver Metastases.
    Margonis GA; Amini N; Andreatos N; Sasaki K; McVey J; Mirza MB; Warner S; Buettner S; Barbon C; Wang J; Pulvirenti A; Angelou A; Kamphues C; Antoniou E; Pikoulis E; Pawlik TM; Kaczirek K; Poultsides G; Wagner D; Endo I; Imai K; Aucejo F; Kreis ME; Wolfgang CL; Weiss MJ
    HPB (Oxford); 2019 Nov; 21(11):1527-1534. PubMed ID: 30979646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases.
    Margonis GA; Buettner S; Andreatos N; Sasaki K; Ijzermans JNM; van Vugt JLA; Pawlik TM; Choti MA; Cameron JL; He J; Wolfgang CL; Weiss MJ
    Ann Surg; 2017 Oct; 266(4):641-649. PubMed ID: 28657938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
    Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients.
    Gholami S; Kemeny NE; Boucher TM; Gönen M; Cercek A; Kingham TP; Balachandran V; Allen P; DeMatteo R; Drebin J; Jarnagin W; D'Angelica M
    Ann Surg; 2020 Aug; 272(2):352-356. PubMed ID: 32675549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
    Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
    Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases.
    Margonis GA; Kim Y; Sasaki K; Samaha M; Buettner S; Amini N; Pawlik TM
    J Surg Oncol; 2016 Sep; 114(3):361-7. PubMed ID: 27264476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
    Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N
    Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.
    Brudvik KW; Mise Y; Chung MH; Chun YS; Kopetz SE; Passot G; Conrad C; Maru DM; Aloia TA; Vauthey JN
    Ann Surg Oncol; 2016 Aug; 23(8):2635-43. PubMed ID: 27016292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
    Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
    Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection.
    Kokudo N; Miki Y; Sugai S; Yanagisawa A; Kato Y; Sakamoto Y; Yamamoto J; Yamaguchi T; Muto T; Makuuchi M
    Arch Surg; 2002 Jul; 137(7):833-40. PubMed ID: 12093342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.